Cara Therapeutics, Inc. (CARA) is a publicly traded company in the Unknown sector. Across all available filings, 23 corporate insiders have executed 344 transactions totaling $47.5M, demonstrating a bearish sentiment with -$8.9M in net insider flow. The most recent transaction on Aug 1, 2024 involved a sale of 4,149 shares valued at $1.5K.
No significant insider buying has been recorded for CARA in the recent period.
No significant insider selling has been recorded for CARA in the recent period.
Based on recent SEC filings, insider sentiment for CARA is bearish with an Insider Alignment Score of 41/100 and a net flow of -$8.9M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Cara Therapeutics, Inc. (CARA) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 23 insiders are actively trading CARA stock, having executed 344 transactions in the past 90 days. The most active insider is Mark Leschly (Executive), who has made 3 transactions totaling $11.6M.
Get notified when executives and directors at CARA file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Aug 1, 2024 | Posner Christopher | Executive | Sale | 4,149 | $0.35 | $1.5K | |
| Jun 4, 2024 | Vogelbaum Martin | Executive | Award | 301,295 | $N/A | $0 | |
| Jun 4, 2024 | Ph.d. Shiff Susan | Executive | Award | 150,647 | $N/A | $0 | |
| Jun 4, 2024 | L. Ives Jeffrey | Executive | Award | 150,647 | $N/A | $0 | |
| Jun 4, 2024 | Lisa Von Moltke | Executive | Award | 150,647 | $N/A | $0 | |
| Jun 4, 2024 | M. Boudreau Helen | Executive | Award | 150,647 | $N/A | $0 | |
| May 2, 2024 | Posner Christopher | Executive | Sale | 3,936 | $0.75 | $3.0K | |
| Apr 5, 2024 | Terrillion Scott | Executive | Sale | 2,753 | $0.83 | $2.3K | |
| Apr 5, 2024 | Goncalves Joana | Executive | Sale | 2,753 | $0.83 | $2.3K | |
| Feb 29, 2024 | Goncalves Joana | Executive | Sale | 3,293 | $0.89 | $2.9K | |
| Feb 29, 2024 | Posner Christopher | Executive | Sale | 5,834 | $0.89 | $5.2K | |
| Feb 29, 2024 | Terrillion Scott | Executive | Sale | 3,293 | $0.89 | $2.9K | |
| Feb 8, 2024 | Posner Christopher | Executive | Sale | 35,575 | $0.53 | $18.9K | |
| Feb 1, 2024 | Posner Christopher | Executive | Sale | 4,981 | $0.55 | $2.7K | |
| Feb 1, 2024 | Posner Christopher | Executive | Award | 62,500 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 198 | $28.2M | 57.1% |
Purchase(P) | 12 | $19.3M | 39.1% |
Exercise(M) | 28 | $1.7M | 3.5% |
Award(A) | 90 | $194.3K | 0.4% |
Conversion(C) | 16 | $0 | 0.0% |
Insider activity at Cara Therapeutics, Inc. shows mixed signals across all time. While $19.3M in purchases indicates some executive confidence,$28.2M in sales balances the picture, resulting in a modest net flow of -$8.9M.23 insiders have been active, with no strong directional conviction evident in the aggregate data. The most active insider, Mark Leschly, has transacted $11.6M during this period.